News
Ionis steps into crowded HAE market with FDA approval for Dawnzera
Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of which have occurred in the last two months. | Since 2008, the FDA has approved 11 treatments for the rare genetic condition hereditary angioedema (HAE),
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Stocktwits on MSN7h
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter. BofA Securities ...
TipRanks on MSN15h
Ionis Pharmaceuticals price target raised to $64 from $63 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares ...
Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.
Ionis Pharmaceuticals (NASDAQ: IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of ...
Hosted on MSN18h
Ionis Pharmaceuticals trading halted, news pending
09:38 EDT Ionis Pharmaceuticals (IONS) trading halted, news pending Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...
Also Read: Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales Sapablursen received FDA Fast Track designation and orphan drug designation in 2024.
Net Margin: Ionis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -46.05%, the company demonstrates strong profitability and effective cost management.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback